Business
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the “Agreement”) with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Comp
About this update from Advanced Biomed Inc.
[{"type":"image","alt":"Advanced Biomed Inc.","displaySize":"","headline":null,"caption":"Advanced Biomed Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/393c670c899a590f026f8c84b8777f43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/faMVLMhp_8Nwf8VXbjmfNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/393c670c899a590f026f8c84b8777f43","width":300,"height":143}},"lazy":false},{"type":"text","content":"Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the “Agreement”) with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Company’s A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro.","length":637,"tagName":"p"},{"type":"text","content":"The feasibility study is a non‑interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi‑Mei Medical Center, with interim comparative data expected in May–June 2026 and full study completion targeted by year‑end 2026. The study will compare ex‑vivo drug sensitivity results generated by the A+PerfusC platform from circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes to assess correlation and predictive performance. It follows the Company’s September 2025 commercial launch of the A+PerfusC integrated perfusion 3D cell culture platform and represents an additional avenue to convert the system’s laboratory strengths into evidence that can be used in clinical practice.","length":798,"tagName":"p"},{"type":"text","content":"This collaboration is significant because it seeks to address a central limitation of current preclinical and guideline‑driven approaches to oncology treatment selection. Two‑dimensional cell culture models and xenograft animal models frequently fail to recapitulate the complex, patient‑spe...